3 Under-the-Radar Artificial Intelligence (AI) Stocks With Explosive Potential

Weave reported 2025 revenue of $239M (+17%) and $12.9M in free cash flow, expanded its addressable market by $7B to $22B and is launching an omnichannel AI receptionist after acquiring TrueLark. Evolv's Q3 2025 revenue jumped 57% to $42.9M and it raised 2025 revenue guidance to $142–145M, citing 1,000+ clients and 3 billion visitors processed. Pagaya posted 2025 revenue of $1.3B (+26%), adjusted EBITDA of $371M (+76%), GAAP net income of $80M, and guided 2026 GAAP net income of $100–150M (≈50% growth at midpoint).

Analysis

The immediate winners are the software and data owners that turn repetitive human tasks into recurring SaaS revenue and reusable training data; think per-location labour savings measured in the low tens of thousands annually and gross margin expansion from automation rather than one-time hardware sales. Second‑order beneficiaries include practice-management EMR vendors (partnership or M&A targets), cloud speech/AI inference vendors (GPU/edge demand), and commercial-liability insurers that can reprice premiums if false negatives fall materially.

Evolv’s strength is a telemetry moat: every pass-through improves classifier calibration, which can compress false alarm rates and reduce operating friction at scale—this converts into a capital-light growth profile once hardware installs roll into subscription renewals, but it also creates concentration risk in sensor suppliers and integration partners. Pagaya’s differentiated signal set behaves like a lower‑volatility tranche inside a securitization: if stable through one recession it should reprice capital costs 100–300 bps lower than peers, yet that math breaks quickly if consumer delinquencies spike or model drift is detected by auditors.

Key near-term catalysts are adoption milestones and third‑party validation: measurable metrics such as conversion rates from live calls to booked appointments, venue roll‑outs for Evolv, and ABS performance prints for Pagaya within the next 6–18 months; regulatory probes, a headline false‑negative/false‑positive security event, or a macro credit shock are realistic tail risks that could unwind multiples within weeks. Time horizons differ: product adoption and margin inflection play out 6–24 months, while systemic credit or legal/regulatory shocks can compress valuations in 0–3 months, arguing for option structures or tight stops on directional exposure.

Key Decisions for Investors

• Long PGY (1.5% AUM): buy 18‑24 month LEAP calls (net‑debit) sized to 1.5% of portfolio. Rationale: asymmetric upside from re‑rating if ABS performance and guidance confirm the data moat; max loss = premium, upside >100% if funding costs compress and institutional demand re‑rates. Monitor: ABS vintage delinquencies on next 2 prints (3–6 months).
• Long EVLV (0.75% AUM): buy shares and hedge with a 6–9 month protective put (cost‑effective collar if premiums rich). Rationale: convex growth if large venues accelerate installs; hedge caps downside from event‑driven headlines or hardware supply shocks. Target: 2–3x upside on positive adoption; cut to zero on material false‑negative incident.
• Conditional WEAV entry (0.5% AUM): staggered buy on KPI trigger — initiate a pilot-sized position if omnichannel AI receptionist converts ≥10% of active install base to paid seats within 6 months; otherwise stay sidelined. Use 9–12 month call spread to limit capital at risk. Rationale: adoption is the key binary; position is cheap optionality until conversion proves out.
• Portfolio hedge / downside insurance (0.5% AUM): buy protection on consumer credit exposure (short CDX IG or buy single‑name protection on stressed subprime names) sized to offset a 20–30% draw in PGY/credit‑exposed holdings. Rationale: preserves optionality in Pagaya and peers if macro‑driven default spike invalidates model backtests within a single quarter.